A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
Phase 4
Completed
- Conditions
- Anemia
- Registration Number
- NCT00117117
- Lead Sponsor
- Amgen
- Brief Summary
The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with Aranesp®.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2423
Inclusion Criteria
- Subjects with nonmyeloid malignancy(ies)
- Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy
Exclusion Criteria
- Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS)
- Unstable cardiac disease or anemia due to other causes
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Patient reported outcomes
- Secondary Outcome Measures
Name Time Method Changes in hemoglobin endpoints and RBC transfusion requirements